II. Definitions
- Acute Abnormal Uterine Bleeding
- Episode of heavy bleeding requires immediate medical evaluation
 
 - Chronic Abnormal Uterine Bleeding
- Six months of Abnormal Uterine Bleeding
 
 - Inter-Menstrual Bleeding
- Bleeding between otherwise normal periods
 
 - 
                          Metrorrhagia
                          
- Change in Amount and Frequency of bleeding, associated with Anovulatory Bleeding
 - Deprecated term ("imprecise")
 - Polymenorrhea: Cycle less than 21 day cycles
 - Oligomenorrhea: Cycle greater than 35 day cycles (>45 days in adolescents)
 
 - 
                          Menorrhagia
                          
- Increase in the amount of bleeding, associated with Ovulatory Bleeding
 - Deprecated term ("imprecise")
 
 - Menometrorrhagia (Metrorrhagia and Menorrhagia)
- Prolonged, irregularly frequent, heavy Menses
 
 - Dysfunctional Uterine Bleeding
- Replaced by "Abnormal Uterine Bleeding"
 
 - Irregular Menses
- Variation of Menstrual Cycle length over prior 12 months >20 days
 
 
III. Epidemiology
- Lifetime risk of Menorrhagia: 33%
 - Prevalence in women of reproductive age: 10-30%
 - Women with Menorrhagia who consult their doctors: 20%
 - Women who have at least one Endometrial Biopsy sampling: 15%
 - Women who have Hysterectomy by age 40 years: 10%
 - Number of hysterectomies for Menorrhagia: 200,000/year
 
IV. Physiology
- See Menstrual Cycle
 
V. Causes
VI. Types: Anovulatory or Ovulatory
- 
                          Anovulatory Bleeding or Metrorrhagia (90%)
- Unopposed Estrogen (Progesterone deficiency)
 - Risk of Endometrial Hyperplasia and ultimately Endometrial Cancer
 
 - 
                          Ovulatory Bleeding or Menorrhagia (10%)
- Inappropriate endometrial response to normal cycle
 - Shortened or prolonged life span of corpus luteum
 - Common causes
- Abnormal Estrogen : Progesterone ratio (low Estrogen)
 - Bleeding Disorder (Von Willebrand Disease)
 
 
 
VII. Symptoms: Bleeding History
- Normal cycles and bleeding
- Menstrual Cycle intervals: 24-38 days
 - Variation between cycles <20 days between cycle lengths over 12 months
 - Menstrual duration: 4.5 to 8 days
 - Normal menstrual volume: 5-80 ml blood per cycle
 
 - 
                          Anovulatory Bleeding
                          
- Change in Amount and Frequency of bleeding
 - Lack of premenstrual signs
- Progesterone absent: no bloating or Breast Pain
 
 
 - 
                          Ovulatory Bleeding
                          
- Premenstrual Symptoms are present
 - Normal Menstrual Cycle intervals (occur every 24 to 38 days)
 - Change in Amount of bleeding
- Menorrhagia
- Patient describes very heavy periods
 - Change pad or tampon every 1-2 hours
- Each saturated pad or tampon contains 20-30 ml blood
 
 - Blood clots >1 inch (2.5 cm)
 - Patient passes over 80 ml blood per cycle
- The definition of 80 ml is no longer recommended
 - Warner (2004) Am J Obstet Gynecol 190:1224-9 [PubMed]
 
 
 - Prolonged bleeding
- Bleeding duration lasts 7 days or more per cycle
 
 
 - Menorrhagia
 
 
VIII. History
- Approach: Key questions
- Pregnancy status
 - Quantify bleeding (20-30 ml blood per saturated pad or tampon)
 - Abdominal or Pelvic Pain
 - Associated symtoms to suggest Hemorrhagic Shock (e.g. Shortness of Breath, Palpitations)
 
 - Red Flags suggestive of serious pathology
- Post-coital Bleeding (e.g. Cervicitis, Cervical Cancer)
 - Perimenopause, postmenopausal patient (Endometrial Cancer)
 
 - 
                          Pelvic Pain
                          
- Consider Pelvic Inflammatory Disease, Endometriosis, structural lesions
 - Consider Trauma (e.g. sexual abuse)
 
 - Pregnancy Symptoms
 - Medication changes
- See Medication Causes of Abnormal Uterine Bleeding
 - See Oral Contraceptive-Related Uterine Bleeding Management
 - Missed Oral Contraceptive pill(s)
 - Recently started or modified medications
 
 - 
                          Bleeding Disorder
                          
- Von Willebrand Disease is most common
 - Consider if onset at Menarche, Family History, bleeding from other sites (e.g. prolonged Epistaxis >10 min)
 - Accounts for 20% of patients with Menorrhagia (esp. adolescent girls)
 
 - Endocrinopathy
- Hypothyroidism and Hyperthyroidism symptoms
 - Hyperandrogenism (e.g. PCOS)
 - Hyperprolactinemia (e.g. Galactorrhea)
 
 
IX. Exam
- 
                          Vital Signs
- Assess for hemodynamic instability
 
 - Findings suggestive of compensated shock (should trigger emergent stabilization)
- Lethargy
 - Tachycardia
 - Tachypnea
 - Peripheral vasconstriction (Cyanosis)
 
 - 
                          General exam
- Thyromegaly
 - Obesity
- Associated with Polycystic Ovary Syndrome
 - Associated with Unopposed Estrogen, Endometrial Hyperplasia and Endometrial Cancer
 
 
 - Abdominal exam
- Peritoneal signs
 - Focal abdominal tenderness
 
 - Vaginal and cervical exam (by speculum or frog-legged position for children)
- Vaginal Lacerations or lesions
 - Vaginitis
 - Vaginal foreign body
 - Cervical polyps or other lesions
 - Cervicitis (e.g. Chlamydia)
 - Cervical os with blood or IUD strings
 
 - Pelvic exam
- Uterine Size
 - Cervical motion tenderness
 - Adnexal tenderness or masses
 - Rectovaginal exam
 
 
X. Labs: Emergency Department
- 
                          Urine Pregnancy Test (bHCG) or blood qualitative Pregnancy Test
- Obtain in all women of reproductive age
 
 - Urinalysis
 - Chlamydia PCR screen
 - Thyroid Stimulating Hormone (TSH)
 - 
                          Complete Blood Count (CBC) with Platelets
- Consider point-of-care Hemoglobin if significant blood loss
 - Consider that Hemoglobin will not reflect full extent of blood loss
 
 - Comprehensive metabolic panel (includes liver and Kidney tests)
 - Coagulation profile (INR, PTT)
 - Type and cross match
 
XI. Labs: Ambulatory - Selected based on Menorrhagia versus Metrorrhagia
- Initial testing
- Urine Pregnancy Test (bHCG) or blood qualitative Pregnancy Test
 - Pap Smear
 - Chlamydia PCR screen
 - Thyroid Stimulating Hormone (TSH)
 - Serum Prolactin
 - Complete Blood Count (CBC) with Platelets
 - Consider Ureaplasma culture
 
 - Additional Testing to Consider
- Glucose to Insulin Ratio
 - Hyperandrogenism labs
 - Coagulation studies
- ProTime (PT)
 - Partial Thromboplastin Time (PTT)
 - Platelet Closure Time (Von Willebrand's Disease suspected)
 
 
 
XII. Diagnostics: Evaluation over age 35-45 years
- Background
- Prior recommendations used age cut-off of 35 years, however Endometrial Cancer is uncommon age <45 years
 - As of 2019, Age over 45 years with Abnormal Uterine Bleeding indicates evaluation
- Consider in age >=35, if persistent or refractory Abnormal Uterine Bleeding, or known Unopposed Estrogen
 
 
 - Combination approach may be best
- Endometrial Cancer Screening
- Endometrial Biopsy (preferred first line) or
 - Dilatation and Curretage
 
 - Structural evaluation
- Transvaginal Ultrasound (preferred first line) or
 - Hysteroscopy
 
 
 - Endometrial Cancer Screening
 - Non-Invasive investigation
- Transvaginal Ultrasound
- Time Ultrasound to end of Menses when endometrium is thinnest (if still menstruating)
 - Endometrial Biopsy for stripe >5 mm
 - Cancer is very unlikely if stripe <4 mm (Negative Predictive Value 99.3%)
 - Incomplete imaging in 10% of cases
- Occurs most commonly if prior uterine procedures, fibroids, Obesity or atypical uterine positioning
 - Saline infusion improves sensitivity (but with an increased False Positive Rate)
 
 
 - Endometrial Biopsy
- See Endometrial Biopsy for efficacy
 - Sensitive and specific for Endometrial Cancer
- Misses Endometrial Polyps and focal lesions
 
 - Insufficient samples are common (no glandular cell)
- Requires other study (non-diagnostic)
 
 
 
 - Transvaginal Ultrasound
 - Invasive procedures (performed by gynecology)
- See Endometrial Cancer Screening
 - Dilatation and Curettage
- No significant advantage over Endometrial Biopsy
 
 - Saline Infusion Sonography
 - Hysteroscopy
- Insufflation with carbon dioxide or warmed saline
- Risk of tumor dissemination
 
 - Flexible 3 mm hysteroscope (Same size as Pipelle)
 - Improves diagnosis with D&C and Endometrial Biopsy
- Identifies most structural lesions (e.g. polyps)
 
 
 - Insufflation with carbon dioxide or warmed saline
 
 
XIII. Evaluation: Protocols
- See Anovulatory Bleeding
 - See Ovulatory Bleeding
 - See Postmenopausal Bleeding
 - See Endometrial Cancer Screening
 - See Abnormal Uterine Bleeding Causes
 - Key conditions to consider and exclude at initial presentation
- Pregnancy (and Ectopic Pregnancy) in women of childbearing age
 - Sexually Transmitted Infection (especially Chlamydia) and Pelvic Inflammatory Disease
 - Other bleeding source
- Gastrointestinal Bleeding (Hematochezia or melana)
 - Hematuria
 
 - Gynecologic cancer
- Endometrial Hyperplasia (and Endometrial Cancer) in women over age 35 years
 - Cervical Cancer
 
 - Other common conditions
 
 
XIV. Management
- Metrorrhagia Management (Anovulatory Bleeding Management)
 - 
                          Menorrhagia Management (Ovulatory Bleeding Management)
- Covers emergent protocols to stop severe uterine and Vaginal Bleeding
 
 
XV. Resources: Patient Education
- Information from your Family Doctor
 
XVI. References
- Mace (2013) Crit Dec Emerg Med 27(2): 13-21
 - Nelson (1997), Fam Prac Recert 19(8):14
 - Apgar (2013) Am Fam Physician 87(12): 836-43 [PubMed]
 - Bradley (2016) Obstet Gynecol 214(1): 31-44 [PubMed]
 - Buchanan (2009) Am Fam Physician 80(10): 1075-88 [PubMed]
 - Sweet (2012) Am Fam Physician 85(1): 35-43 [PubMed]
 - Wouk (2019) Am Fam Physician 99(7): 435-43 [PubMed]